Highnoon Laboratories (KAR:HINOON) Cyclically Adjusted Revenue per Share: ₨310.50 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:HINOON Highnoon Laboratories Ltd KAR:HINOON
96 GF Score
Price ₨1,003.54
GF Value ₨1,031.55
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Highnoon Laboratories Cyclically Adjusted Revenue per Share?

Highnoon Laboratories KAR:HINOON +0.86% 96 Cyclically Adjusted Revenue per Share is ₨310.50 as of Mar. 2026. GuruFocus rates KAR:HINOON with a GF Score™ of 96/100 and a GF Value™ of ₨1,031.55 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Highnoon Laboratories's adjusted revenue per share for the three months ended in Mar. 2026 was ₨141.933. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₨310.50 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Highnoon Laboratories's average Cyclically Adjusted Revenue Growth Rate was 19.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-17), Highnoon Laboratories's current stock price is ₨1003.54. Highnoon Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₨310.50. Highnoon Laboratories's Cyclically Adjusted PS Ratio of today is 3.23.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Highnoon Laboratories was 4.48. The lowest was 1.79. And the median was 3.16.


Highnoon Laboratories  (KAR:HINOON) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Highnoon Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1003.54/310.50
=3.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Highnoon Laboratories was 4.48. The lowest was 1.79. And the median was 3.16.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Highnoon Laboratories Cyclically Adjusted Revenue per Share Related Terms


Highnoon Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Highnoon Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Highnoon Laboratories Cyclically Adjusted Revenue per Share Chart

Highnoon Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 203.32 246.59 293.93

Highnoon Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 260.52 271.47 283.71 293.93 310.50

KAR:HINOON vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Highnoon Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Highnoon Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Highnoon Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Highnoon Laboratories's Cyclically Adjusted PS Ratio falls into.


KAR:HINOON
96GF Score
Highnoon Laboratories Ltd KAR:HINOON
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Highnoon Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Highnoon Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=141.933/330.2130*330.2130
=141.933

Current CPI (Mar. 2026) = 330.2130.

Highnoon Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 24.588 241.018 33.687
201609 22.731 241.428 31.090
201612 17.002 241.432 23.254
201703 25.829 243.801 34.984
201706 28.133 244.955 37.925
201709 27.426 246.819 36.693
201712 31.326 246.524 41.960
201803 30.924 249.554 40.919
201806 36.176 251.989 47.406
201809 35.627 252.439 46.603
201812 38.895 251.233 51.122
201903 39.987 254.202 51.944
201906 43.211 256.143 55.707
201909 42.507 256.759 54.667
201912 45.046 256.974 57.884
202003 48.412 258.115 61.935
202006 47.031 257.797 60.242
202009 53.650 260.280 68.065
202012 52.834 260.474 66.980
202103 58.809 264.877 73.315
202106 61.392 271.696 74.614
202109 60.577 274.310 72.922
202112 64.599 278.802 76.511
202203 70.875 287.504 81.404
202206 81.681 296.311 91.026
202209 79.117 296.808 88.021
202212 71.416 296.797 79.457
202303 93.504 301.836 102.295
202306 93.593 305.109 101.294
202309 97.253 307.789 104.338
202312 88.702 306.746 95.488
202403 115.926 312.332 122.563
202406 111.295 314.175 116.976
202409 118.629 315.301 124.239
202412 119.226 315.605 124.744
202503 132.607 319.799 136.925
202506 116.248 322.561 119.006
202509 130.301 324.800 132.473
202512 139.707 324.054 142.362
202603 141.933 330.213 141.933

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₨310.50 mean?
Highnoon Laboratories (KAR:HINOON) has a Cyclically Adjusted Revenue per Share of ₨310.50 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Highnoon Laboratories and its competitors.
Is Highnoon Laboratories' Cyclically Adjusted Revenue per Share too high?
Highnoon Laboratories' current Cyclically Adjusted Revenue per Share is ₨310.50. Overall, Highnoon Laboratories has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Highnoon Laboratories' Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Highnoon Laboratories' Cyclically Adjusted Revenue per Share of ₨310.50 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Highnoon Laboratories and its competitors. Highnoon Laboratories's current Cyclically Adjusted Revenue per Share is ₨310.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Highnoon Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Highnoon Laboratories (KAR:HINOON) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,031.55, compared to a current price of ₨1,003.54 — trading 2.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₨310.50. Highnoon Laboratories' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Highnoon Laboratories (KAR:HINOON), the current Cyclically Adjusted Revenue per Share is ₨310.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Highnoon Laboratories (KAR:HINOON) Overvalued in 2026?

Based on GuruFocus' analysis, Highnoon Laboratories stock appears to be undervalued. The current stock price of ₨1,003.54 is trading 2.7% below its estimated GF Value™ of ₨1,031.55. GuruFocus considers Highnoon Laboratories to be Fairly Valued.

Key valuation signals for KAR:HINOON:

  • Cyclically Adjusted Revenue per Share: ₨310.50
  • GF Value™: ₨1,031.55 vs. price of ₨1,003.54 (2.7% below fair value)
  • GF Score™: 96/100 with 3 warning signs

No single metric tells the full story. See the KAR:HINOON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Highnoon Laboratories Business Description

Address Jail Road, 901-9th floor, Tricon Corporate Center 73-E, Lahore, PAK
Highnoon Laboratories Ltd is a company engaged in the manufacture, import, sale, and marketing of pharmaceutical and allied consumer products. It focuses on the alimentary tract and metabolism, antihistamines, anti-infectives, cardiovascular, endocrine, hematology, musculoskeletal, nervous system, parasitology, respiratory, and urinary. Its products include AIRTAL (Aceclofenac); ARIA (ketotifen); ARTECXCIN, and artrodar (diacerein). Its other products include Asthavent, AXESOME, Bezisox, Betatec, and many more.
96GF Score

Get the complete analysis for KAR:HINOON

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨1,003.54
Price
₨1,031.55
GF Value